Healthy volunteers test Noribogaine's safety in Early-Stage trial
NCT ID NCT06480981
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and drug levels of noribogaine in 55 healthy adults aged 18 to 45. Participants received either the drug or a placebo, and researchers measured how the drug was processed by the body. The goal was to gather safety information, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Richmond Pharmacology
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New painkiller injection could cut opioid use after chest surgery